SEARCH:   Advanced

Blood, 15 February 2008, Vol. 111, No. 4, pp. 1767-1772. Prepublished online as a Blood First Edition Paper on December 5, 2007; DOI 10.1182/blood-2007-07-097543. This Article Full Text (PDF) All Versions of this Article: blood-2007-07-097543v1 111/4/1767    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Anderlini, P. Articles by Champlin, R. E. Search for Related Content PubMed PubMed Citation Articles by Anderlini, P. Articles by Champlin, R. E. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted July 18, 2007 Accepted November 20, 2007 Biologic and molecular effects of granulocyte colony-stimulating factor in normal individuals: recent findings and current challenges Paolo Anderlini* and Richard E. Champlin Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States * Corresponding author; email: panderli{at}mdanderson.org. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used in normal donors for collection of peripheral blood progenitor cells (PBPCs) for allogeneic transplantation and granulocytes for transfusion. The spectrum of its biologic and molecular activities in normal individuals is coming into sharper focus, creating a unique set of challenges and clarifying the need to monitor and safeguard donor safety. Accumulating evidence indicates that rhG-CSF effects are not limited to the myeloid cell lineage. This may reflect the presence of functional G-CSF receptors on other cell types and tissues, as well as rhG-CSF-induced modulation of cytokine networks. These effects are important, not only for normal donor management but for the evolving field of regenerative medicine, where patients with coronary artery disease and other disorders are increasingly exposed to the cytokine. In addition, while most of rhG-CSF-induced effects are transient and self-limiting, preliminary, provocative data have suggested the possibility of a more durable effect on the chromosomal integrity of lymphocytes. While these reports have not been validated and have been subject to criticism, they are prompting prospective studies and monitoring efforts to determine if there is a significant risk of long-term adverse events (e.g. hematological malignancies) in normal PBPC and granulocyte donors. Based on the totality of information that is currently available, the administration of rhG-CSF to normal donors for the purpose of PBPC donation continues to have a favorable risk-benefit profile. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Maury, C. Cordonnier, M. Kuentz, D. Klatzmann, and J. L. Cohen Searching for factors to improve the antileukemic effect of donor lymphocyte infusion Blood, May 15, 2008; 111(10): 5256 - 5256. [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020